AI Article Synopsis
- - The article introduces a new protocol for the inhibitory avoidance test designed to improve the assessment of cognitive enhancers in reversing memory deficits caused by scopolamine, aiming for greater reliability and less variability in results.
- - This protocol includes two initial trials followed by a retention trial, successfully differentiating between outcomes in scopolamine-treated and control groups, and validating the effectiveness of known acetylcholinesterase inhibitors.
- - The study confirms the protocol's consistency over three years and suggests it requires a small sample size (5-12 mice) to detect significant drug effects, enhancing efficiency for pharmacological screening of cognitive enhancers.
Article Abstract
In the present article, we describe a new protocol for the inhibitory avoidance test, with a dual purpose: (1) to provide a less variable and more reliable assessment of the efficacy of potential cognitive enhancers in antagonizing scopolamine-induced long-term-memory deficits, and (2) to secure a high throughput for pharmacological screening of cognitive enhancers. The new protocol consists of two acquisition trials that are followed 24 h later by a single retention trial. In the present study, this protocol clearly dissociated the frequency distributions of retention latencies between scopolamine- and vehicle-treated groups and allowed validation by means of two acetylcholinesterase inhibitors-tacrine and donepezil-that proved to be active in counteracting the scopolamine-induced memory deficit. This protocol also produced stability of the behavioral response to pharmacological agents over a 3-year period. A statistical power analysis indicated that, depending on the efficacy of the drug/dose, a sample size of 5-12 mice was required in order to show a reversal of the scopolamine-induced memory deficit. The double-trial acquisition protocol is suitable for testing cognitive enhancers, while also providing a clearly enhanced throughput.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3758/BRM.41.3.805 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Insights into Facial Variation and Craniofacial Development: Unraveling the Interplay of Genes, Expression Patterns, and Evolutionary Significance.
Mol Biotechnol
December 2024
Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, 46000, Pakistan.
The development of genome technology has opened new possibilities for comparative primate genomics. Non-human primates share approximately 98% genome similarity and provides vital information into the genetic similarities and variances among species utilized as disease models. DNA study links unique genetic variations to common facial attributes such as nose and eyes.
View Article and Find Full Text PDFIdentification of Pappa and Sall3 as Gli3 direct target genes acting downstream of cilia signaling in corticogenesis.
Cereb Cortex
December 2024
Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
The cerebral cortex is critical for advanced cognitive functions and relies on a vast network of neurons to carry out its highly intricate neural tasks. Generating cortical neurons in accurate numbers hinges on cell signaling orchestrated by primary cilia to coordinate the proliferation and differentiation of cortical stem cells. While recent research has shed light on multiple ciliary roles in corticogenesis, specific mechanisms downstream of cilia signaling remain largely unexplored.
View Article and Find Full Text PDFAbnormal Astrocyte Heterogeneity in the Dentate Gyrus of Rats Prone to Audiogenic Seizures Can Be Corrected by the Nootropic Drug Piracetam.
Hippocampus
January 2025
Sechenov Institute of Evolutionary Physiology and Biochemistry, The Russian Academy of Sciences, Saint Petersburg, Russia.
Accumulating evidence indicates that inherited astrocyte dysfunction can be a primary trigger for epilepsy development; however, the available data are rather limited. In addition, astrocytes are considered as a perspective target for the design of novel and improvement of the existing antiepileptic therapy. Piracetam and related nootropic drugs are widely used in the therapy of various epileptic disorders, but detailed mechanisms of racetams action and, in particular, their effects on glial functions are poorly understood.
View Article and Find Full Text PDFFunctionalized Graphene Quantum Dots as an Eco-Friendly Fluorescent Probe for Galantamine Analysis: Greenness Evaluation With Application to Pharmacokinetics Monitoring.
Luminescence
December 2024
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
In this study, the use of functionalized graphene quantum dots (GQDs) as a fluorescent probe has been investigated for the quantitative determination of galantamine, a choline esterase inhibitor used for the treatment of Alzheimer's disease. The GQDs exhibit a significant quenching in their fluorescence intensity upon interaction with galantamine allowing for sensitive and selective detection of the drug. This quenching process follows a dynamic pattern with a linear relationship between fluorescence intensity and the concentration of galantamine.
View Article and Find Full Text PDFEffects of valproic acid, levetiracetam, carbamazepine, and oxcarbazepine on thyroid function tests in children.
Rev Assoc Med Bras (1992)
December 2024
Pamukkale University, School of Medicine, Department of Radiology - Denizli, Turkey.
Objective: The aim of the study was to evaluate the effects of commonly used medications for epilepsy on thyroid function tests in children.
Methods: Epileptic children treated with valproic acid, levetiracetam, carbamazepine, and oxcarbazepine were retrospectively examined along with a healthy control group. Levels of free thyroxine 4 and thyroid-stimulating hormone were compared.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!